Center Laboratories Past Earnings Performance
Past criteria checks 0/6
Center Laboratories's earnings have been declining at an average annual rate of -48.2%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 72% per year.
Key information
-48.2%
Earnings growth rate
-49.8%
EPS growth rate
Pharmaceuticals Industry Growth | 18.5% |
Revenue growth rate | -72.0% |
Return on equity | -5.2% |
Net Margin | -71.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Center Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,394 | -995 | 457 | 83 |
30 Sep 23 | 1,227 | -903 | 415 | 72 |
30 Jun 23 | 1,058 | -1,018 | 380 | 59 |
31 Mar 23 | 951 | -265 | 326 | 55 |
31 Dec 22 | 768 | 102 | 288 | 47 |
30 Sep 22 | 650 | -623 | 7 | 64 |
30 Jun 22 | 566 | -342 | -154 | 68 |
31 Mar 22 | 494 | 1,057 | -30 | 72 |
31 Dec 21 | 500 | 1,816 | 291 | 75 |
30 Sep 21 | 551 | 3,898 | 682 | 76 |
30 Jun 21 | 594 | 5,659 | 1,112 | 96 |
31 Mar 21 | 567 | 5,695 | 977 | 103 |
31 Dec 20 | 717 | 3,786 | 693 | 129 |
30 Sep 20 | 924 | 2,275 | 657 | 174 |
30 Jun 20 | 1,139 | 1,357 | 452 | 177 |
31 Mar 20 | 1,386 | 138 | 508 | 208 |
31 Dec 19 | 1,438 | -286 | 503 | 206 |
30 Sep 19 | 3,691 | 3,769 | 1,529 | 208 |
30 Jun 19 | 9,356 | 5,321 | 3,856 | 372 |
31 Mar 19 | 16,118 | 5,423 | 6,197 | 625 |
31 Dec 18 | 21,648 | 6,084 | 8,320 | 732 |
30 Sep 18 | 24,900 | 2,407 | 9,391 | 955 |
30 Jun 18 | 23,950 | 876 | 8,703 | 939 |
31 Mar 18 | 21,475 | 718 | 7,715 | 820 |
31 Dec 17 | 19,392 | 250 | 6,757 | 806 |
30 Sep 17 | 18,016 | -64 | 6,232 | 735 |
30 Jun 17 | 16,477 | 90 | 5,657 | 669 |
31 Mar 17 | 15,588 | 58 | 5,473 | 575 |
31 Dec 16 | 15,040 | 19 | 5,305 | 518 |
30 Sep 16 | 14,541 | 703 | 4,943 | 328 |
30 Jun 16 | 13,269 | 490 | 4,521 | 243 |
31 Mar 16 | 9,804 | 437 | 3,351 | 172 |
31 Dec 15 | 6,792 | 422 | 2,335 | 124 |
30 Sep 15 | 3,026 | 135 | 1,077 | 123 |
30 Jun 15 | 1,008 | 22 | 374 | 123 |
31 Mar 15 | 944 | 241 | 315 | 141 |
31 Dec 14 | 899 | 333 | 282 | 148 |
30 Sep 14 | 883 | 40 | 225 | 147 |
30 Jun 14 | 824 | 216 | 211 | 148 |
31 Mar 14 | 775 | 73 | 193 | 138 |
31 Dec 13 | 742 | 52 | 186 | 129 |
30 Sep 13 | 693 | 125 | 175 | 140 |
30 Jun 13 | 688 | 78 | 175 | 142 |
Quality Earnings: 4123 is currently unprofitable.
Growing Profit Margin: 4123 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4123 is unprofitable, and losses have increased over the past 5 years at a rate of 48.2% per year.
Accelerating Growth: Unable to compare 4123's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4123 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-15%).
Return on Equity
High ROE: 4123 has a negative Return on Equity (-5.18%), as it is currently unprofitable.